CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Baird, John H., Frank, Matthew J., Craig, Juliana, Patel, Shabnum, Spiegel, Jay Y., Sahaf, Bita, Oak, Jean S., Younes, Sheren F., Ozawa, Michael G., Yang, Eric, Natkunam, Yasodha, Tamaresis, John, Ehlinger, Zachary, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Davis, Kara L., Ramakrishna, Sneha, Schultz, Liora, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Feldman, Steven A., Mackall, Crystal L., Miklos, David B., Muffly, Lori
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2021
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085484/
https://ncbi.nlm.nih.gov/pubmed/33512414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009432
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares